Insider trade

Director sold ~$520K of CORT shares in the open market

Traded Aug 14, 2026 · Filed Aug 19, 2026

Why it stands out

A board member of Corcept Therapeutics sold $520K of Corcept Therapeutics shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

DirectorIndirect holding$500K–$1MPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$520,214

Shares × reported transaction price

Timing vs results

16 days after results of Jul 29, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+0.7%	-0.4%	+1.1%
30 days	-7.3%	-1.0%	-6.4%

Past results only. Not a forecast.

This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.01 to $112.00 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

3w ago

Derivative exercise or conversion — not an open-market buy.

3w ago

Derivative exercise or conversion — not an open-market buy.

Scheduled in advance3w ago